Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JLOLU
ADC Name
WO2020063673A1 ADC-3
Synonyms
WO2020063673A1_ADC 3
   Click to Show/Hide
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Astrocytoma [ICD11:2F36]
Investigative
Kidney cancer [ICD11:2C90-2C91]
Investigative
Melanoma [ICD11:2C30]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
7.58
Structure
Antibody Name
Anti-CD276 mAb h1702DS
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2020063673A1_ADC-3 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.51
nM
A-375 cells
Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50) 
1.89
nM
Detroit 562 cells
Pharyngeal squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.91
nM
Calu-6 cells
Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
3.78
nM
U-87MG cells
Glioblastoma
Half Maximal Inhibitory Concentration (IC50) 
13.1
nM
A498 cells
Renal carcinoma
Half Maximal Inhibitory Concentration (IC50) 
36.8
nM
CHO-K1 cells
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.51 nM Positive CD276 expression (CD276 +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Amelanotic melanoma A-375 cells CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.89 nM Positive CD276 expression (CD276 +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Pharyngeal squamous cell carcinoma Detroit 562 cells CVCL_1171
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.91 nM Positive CD276 expression (CD276 +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Lung adenocarcinoma Calu-6 cells CVCL_0236
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 3.78 nM Positive CD276 expression (CD276 +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 13.10 nM Positive CD276 expression (CD276 +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Renal carcinoma A498 cells CVCL_1056
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 36.80 nM Negative CD276 expression (CD276 -)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Normal CHO-K1 cells CVCL_0214
References
Ref 1 Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof; 2020-04-02.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.